# ANTI-IDIOTYPE ANTIBODIES:  ANTIGENS FOR HUMAN TUMORS

> **NIH NIH R01** · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · 1987 · $118,476

## Abstract

This research extends previously published studies on the biology and in
vitro immunity of cultured colon tumor cells.  After establishing a set of
characterized human colon cancer cell lines (LS180, L174T, and their
clones) exhibiting malignant properties and reflecting characteristics of
the original tumor, we produced a series of monoclonal antibodies (Mab)
against LS174T tumor cells, of which 5E113 is selective for human colon
cancer.  Partially purified tumor antigens bind 5E113 in ELISA assay and
competitively block antibody binding to the tumor cell.  An in vitro system
has been developed to study immunogenicity of tumor antigens.  Research
will test the hypothesis that internal image anti-idiotypic (Id) antibodies
produced against Mabs such as 5E113 represent mirror images of the
antigen-combining site of the original 5E113 antibody, mimicking the colon
tumor antigen.  The specific aims are to:  (1) produce Id antibodies toward
Mab reactive with human colon cancer; and (2) assess the activity of Id
antibodies as antigens in humoral and cell-mediated immune assays.  Id
antibodies will be produced in one of three alternative host models:  (1)
New Zealand white rabbits immunized to 5E113 Mab to human colon cancer,
followed by affinity column chromatography isolation of Id antibodies; (2)
Wistar-Furth rats tolerized to normal BALB/c mouse immunoglobulins prior to
immunization with Mab; and (3) normal BALB/c spleen cells immunized in
vitro with Mab.  Experimental approaches will evaluate the antigenic
characteristics of the Id antibodies, including Id antibody binding onto
"immune" lymphocytes from colon cancer patients, either from peripheral
blood or dispersed from the tumor mass. The immunogenicity of Id
antibodies, to determine the range of antigenic activities and elicit
responses toward colon tumors, will be tested by:  (1) producing antibody
and T-cell responses in BALB/c mice directed against LS174T cells tested in
vitro; (2) eliciting in vitro secondary immune responses from colon cancer
immune murine and human (patient) lymphocytes; and (3) generation of in
vitro primary cellular immunity in naive BALB/c and human lymphocytes to
human colon cancer antigens.  If the Id antibody is found to serve as an
effective colon tumor antigen, further studies to evaluate immunodiagnostic
and immunotherapeutic protocols in patients will be warranted.  (IT)

## Key facts

- **NIH application ID:** 3179772
- **Project number:** 5R01CA040168-03
- **Recipient organization:** UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- **SAM.gov UEI:** ZUFBNVZ587D4
- **Principal Investigator:** LYNNE P RUTZKY
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $118,476
- **Award type:** 5
- **Project period:** 1985-07-01 → 1988-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3179772

## Citation

> US National Institutes of Health, RePORTER application 3179772, ANTI-IDIOTYPE ANTIBODIES:  ANTIGENS FOR HUMAN TUMORS (5R01CA040168-03). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3179772. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*